Vaccine Partnering Terms and Agreements

NEW YORK, June 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Vaccine Partnering Terms and Agreements

http://www.reportlinker.com/p0655260/Vaccine-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Summary

The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in vaccine and adjuvant partnering deals

Deal terms analysis

Partnering agreement structure

Partnering contract documents

Top deals by value

Most active dealmakers

Average deal terms for vaccines

Description

The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1,500 links to online copies of actual vaccine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in vaccine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading vaccine deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of vaccine deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of vaccine partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in vaccine partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of vaccine technologies and products.

Vaccine Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to vaccine trends and structure of deals entered into by leading companies worldwide.

Vaccine Partnering Terms and Agreements includes:

Trends in vaccine dealmaking in the biopharma industry since 2007

Analysis of vaccine deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life vaccine deals

Access to over 1,500 vaccine deal documents

The leading vaccine deals by value since 2007

Most active vaccine dealmakers since 2007

The leading vaccine partnering resources

In Vaccine Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Vaccine Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 vaccine deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise vaccine rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Benefits

Vaccine Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of vaccine and adjuvant deal trends since 2007

Access to headline, upfront, milestone and royalty data

Analysis of the structure of vaccine agreements with numerous real life case studies

Comprehensive access to over 1500 actual vaccine contracts entered into by the world's biopharma companies

Detailed access to actual vaccine contracts enter into by the leading fifty bigpharma companies

Insight into the terms included in a vaccine agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in vaccine dealmaking

2.1. Introduction

2.2. Companion vaccine over the years

2.3. Bigpharma vaccine dealmaking activity

2.4. Bigpharma not active in vaccines

2.5. Vaccine partnering by deal type

2.6. Vaccine partnering by disease type

2.7 Average deal terms for vaccine

2.7.1 Vaccine headline values

2.7.2 Vaccine upfront payments

2.7.3 Vaccine milestone payments

2.7.4 Vaccine royalty rates

Chapter 3 – Leading vaccine deals

3.1. Introduction

3.2. Top vaccine deals by value

3.3. Top vaccine deals involving bigpharma

Chapter 4 – Bigpharma vaccine deals

4.1. Introduction

4.2. How to use bigpharma vaccine partnering deals

4.3. Bigpharma vaccine partnering company profiles

Abbott

Actavis

Actelion

Allergan

Amgen

Aspen Pharmacare

Astellas

AstraZeneca

Baxter International

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

CSL

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Eli Lilly

Endo Pharmaceuticals

Forest Laboratories

Galderma

Gilead Sciences

GlaxoSmithKline

Grifols

Hospira

Johnson & Johnson

Kyowa Hakko Kirin

Lundbeck

Menarini

Merck & Co

Merck KGaA

Mitsubishi Tanabe

Mylan

Novartis

Novo Nordisk

Otsuka

Pfizer

Purdue

Roche

Sanofi

Servier

Shionogi

Takeda

Teva

UCB

Valeant

Warner Chilcott

Watson

Chapter 5 – Vaccine dealmaking directory

5.1. Introduction

5.2. Company A-Z

5.3. By stage of development

Discovery

Pre-clinical

Phase I

Phase II

Phase III

Registration

Marketed

5.4. By deal type

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation

Grant

Joint venture

Licensing

Litigation

Manufacturing

Marketing

Material transfer

Option

Promotion

Research

Royalty financing

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty

5.5. By therapy area

Anesthetics

Cardiovascular

Central nervous system

Dental

Dermatology

Gastrointestinal

Genitourinary

Hematology

Hospital care

Immunology

Infectives

Inflammatory

Metabolic

Musculoskeletal

Oncology

Ophthalmics

Psychiatry

Public health

Respiratory

Sexual health

5.6. By associated technology type

Adjuvant

Chapter 6 – Partnering resource center

6.1. Online partnering

6.2. Partnering events

6.3. Further reading on dealmaking

Appendices

Appendix 1 – Deal type definitions

Appendix 2 – Example vaccine partnering agreement

About Wildwood Ventures

Figures in report

Figure 1: Vaccine partnering since 2007

Figure 2: Bigpharma – top 50 – vaccine deals 2007 to 2012

Figure 3: Bigpharma vaccine deal frequency – 2007 to 2012

Figure 4: Inactive bigpharma in vaccine partnering 2007-2012

Figure 5: Vaccine partnering by deal type since 2007

Figure 6: Vaccine partnering by disease type since 2007

Figure 7: Vaccine partnering by infectives target since 2007

Figure 8: Vaccine partnering by oncology target since 2007

Figure 9: Vaccine deals with a headline value – by stage of development

Figure 10: Vaccine deal headline value distribution, US$million – discovery stage

Figure 11: Vaccine deal headline value distribution, US$million – preclinic stage

Figure 12: Vaccine deal headline value distribution, US$million – phase I stage

Figure 13: Vaccine deal headline value distribution, US$million – phase II stage

Figure 14: Vaccine deal headline value distribution, US$million – phase III stage

Figure 15: Vaccine deal headline value distribution, US$million – marketed stage

Figure 16: Vaccine deal headline value – median value by stage of development

Figure 17: Vaccine deals with upfront payment values – by stage of development

Figure 18: Vaccine deal upfront payment distribution, US$million – discovery stage deals

Figure 19: Vaccine deal upfront payment distribution, US$million – prelinic stage deals

Figure 20: Vaccine deal upfront payment distribution, US$million – phase I stage deals

Figure 21: Vaccine deal upfront payment distribution, US$million – phase II stage deals

Figure 22: Vaccine deal upfront payment distribution, US$million – phase III stage deals

Figure 23: Vaccine deal upfront payment distribution, US$million – marketed stage deals

Figure 24: Vaccine deal upfront value – median value by stage of development

Figure 25: Vaccine deals with milestone payment – by stage of development

Figure 26: Vaccine deal milestone payment distribution, US$million – discovery stage deals

Figure 27: Vaccine deal milestone payment distribution, US$million – prelinic stage deals

Figure 28: Vaccine deal milestone payment distribution, US$million – phase I stage deals

Figure 29: Vaccine deal milestone payment distribution, US$million – phase II stage deals

Figure 30: Vaccine deal milestone payment distribution, US$million – phase III stage deals

Figure 31: Vaccine deal milestone payment distribution, US$million – marketed stage deals

Figure 32: Vaccine deal milestone payments – median value by stage of development

Figure 33: Vaccine deals with royalty rates

Figure 34: Top vaccine deals by value since 2007

Figure 35: Top vaccine deals signed by bigpharma value since 2007

Figure 36: Recent deals (Jan 2007 to May 2012) - By therapy area (Anesthetics

Figure 37: Recent deals (Jan 2007 to May 2012) - By therapy area (Cardiovascular

Figure 38: Recent deals (Jan 2007 to May 2012) - By therapy area (Central Nervous System)

Figure 39: Recent deals (Jan 2007 to May 2012) - By therapy area (Dental)

Figure 40: Recent deals (Jan 2007 to May 2012) - By therapy area (Dermatology)

Figure 41: Recent deals (Jan 2007 to May 2012) - By therapy area (Gastrointestinal)

Figure 42: Recent deals (Jan 2007 to May 2012) - By therapy area (Genitourinary)

Figure 43: Recent deals (Jan 2007 to May 2012) - By therapy area (Hematology)

Figure 44: Recent deals (Jan 2007 to May 2012) - By therapy area (Hospital care)

Figure 45: Recent deals (Jan 2007 to May 2012) - By therapy area (Immunology)

Figure 46: Recent deals (Jan 2007 to May 2012) - By therapy area (Infectives)

Figure 47: Recent deals (Jan 2007 to May 2012) - By therapy area (Inflammatory)

Figure 48: Recent deals (Jan 2007 to May 2012) - By therapy area (Metabolic)

Figure 49: Recent deals (Jan 2007 to May 2012) - By therapy area (Musculoskeletal)

Figure 50: Recent deals (Jan 2007 to May 2012) - By therapy area (Oncology)

Figure 51: Recent deals (Jan 2007 to May 2012) - By therapy area (Ophthalmics)

Figure 52: Recent deals (Jan 2007 to May 2012) - By therapy area (Psychiatry)

Figure 53: Recent deals (Jan 2007 to May 2012) - By therapy area (Public health)

Figure 54: Recent deals (Jan 2007 to May 2012) - By therapy area (Respiratory)

Figure 55: Recent deals (Jan 2007 to May 2012) - By therapy area (Sexual health)

Figure 56: Online partnering resources

Figure 57: Forthcoming partnering events

Figure 58: Deal type definitions

Figure 59: Vaccine partnering agreement between Novavax and LG Life Sciences, March 2011

To order this report:

: Vaccine Partnering Terms and Agreements

__________________________

Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker